Business
ETST & Cannabis Therapeutics Inc. Announce its Cannabis Cannabinoid-Based Nutraceutical Patent & Generic Pharmaceutical Drug Timeline & Update.
ETST & Cannabis Therapeutics Inc. Announce its Cannabis Cannabinoid-Based Nutraceutical Patent & Generic Pharmaceutical Drug Timeline & Update..
About this update from Earth Science Tech, Inc.
[{"type":"text","content":"\n\n Hollywood, March 06, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) (\"ETST\" or \"the Company\"), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices based company is proud to announce that its wholly owned subsidiary Cannabis Therapeutics timeline for its cannabis cannabinoid-based nutraceutical patent and generic pharmaceutical drug completion.\n At a meeting with the company's Advisory Board on Tuesday, February 28th at Le Centre Québecois d'Innovation en Biotechnologie (CQIB) in Laval, Québec; the scientists concluded that the improved CBD Hemp Oil food supplement was ready to move to prototyping, and then to be fast tracked to commercialization. In addition, two cannabinoid-based generic pharmaceutical drugs will be ready for pre-market clinical trials related to drug bioavailability by Q3 2017. Depending on the time needed to properly conduct the clinical trials, both of the pharmaceutical drugs looks to be completed by the end of 2017 or beginning of 2018. The first or these two generic drugs, an anti-breast cancer drug, is an important advance for the company as breast cancer affects more women worldwide than any other cancer. The components of the anti-breast cancer drug that Cannabis Therapeutics is bringing to market are contained in the World Health Organization’s current Model List of Essential Medicines (2015). The WHO Model Complementary List indicates the essential medicines needed to treat priority diseases, such as breast cancer, by any healthcare system.Other items to note from the meeting: Dr. Michel Aubé, CEO and Chief Scientific Officer of ETST and Cannabis Therapeutics, Inc., was in attendance with Dr. Chandra Panchal, Dr. Domenico Fuoco, and Dr. Moutih Rafei.Apart from the three new products for 2017, three other cannabinoid pharmaceutical and nutraceutical product research projects received official start-up approval with product release targeted for YE2018.As predicted, the company also formally launched its R&D partnership with Smart Medicine, Inc. an independent laboratory that provides laboratory and technical services to ETST in their facility at CQIB.The company's Advisory Board agreed to have monthly meetings at C...